Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Prothena Co. plc (NASDAQ:PRTA – Get Rating) Director Shane Cooke sold 5,000 shares of Prothena stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $61.04, for a total value of $305,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shane Cooke also recently made the following trade(s):
- On Thursday, November 10th, Shane Cooke sold 5,000 shares of Prothena stock. The stock was sold at an average price of $56.17, for a total transaction of $280,850.00.
- On Monday, October 10th, Shane Cooke sold 5,000 shares of Prothena stock. The stock was sold at an average price of $55.91, for a total transaction of $279,550.00.
- On Wednesday, September 28th, Shane Cooke sold 10,000 shares of Prothena stock. The stock was sold at an average price of $48.09, for a total transaction of $480,900.00.
Prothena Stock Performance
Shares of NASDAQ:PRTA traded up $3.19 during midday trading on Monday, reaching $61.55. 485,571 shares of the company’s stock traded hands, compared to its average volume of 521,720. The company has a fifty day simple moving average of $58.56 and a two-hundred day simple moving average of $40.29. Prothena Co. plc has a 1 year low of $21.06 and a 1 year high of $66.47. The company has a market cap of $2.98 billion, a P/E ratio of -18.43 and a beta of 0.50.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on PRTA shares. Bank of America upgraded shares of Prothena from a “neutral” rating to a “buy” rating and upped their price objective for the company from $45.00 to $65.00 in a report on Wednesday, September 28th. Oppenheimer upped their price objective on shares of Prothena from $110.00 to $120.00 in a report on Tuesday, November 15th. JMP Securities upped their price objective on shares of Prothena from $50.00 to $81.00 in a report on Wednesday, September 28th. StockNews.com assumed coverage on Prothena in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Finally, Citigroup upped their target price on Prothena from $65.00 to $71.00 and gave the company a “buy” rating in a research report on Monday, October 24th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Prothena has an average rating of “Moderate Buy” and a consensus target price of $78.40.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its stake in shares of Prothena by 89.4% in the 1st quarter. Victory Capital Management Inc. now owns 15,410 shares of the biotechnology company’s stock worth $449,000 after acquiring an additional 7,273 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Prothena by 30.2% during the 1st quarter. New York State Common Retirement Fund now owns 40,073 shares of the biotechnology company’s stock worth $1,465,000 after purchasing an additional 9,292 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Prothena by 11.4% during the 1st quarter. Teacher Retirement System of Texas now owns 6,685 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 685 shares during the period. Swiss National Bank grew its holdings in shares of Prothena by 11.2% during the 1st quarter. Swiss National Bank now owns 77,200 shares of the biotechnology company’s stock worth $2,823,000 after purchasing an additional 7,800 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in shares of Prothena by 134.9% during the 1st quarter. GSA Capital Partners LLP now owns 31,142 shares of the biotechnology company’s stock worth $1,139,000 after purchasing an additional 17,883 shares during the period. 93.92% of the stock is owned by institutional investors and hedge funds.
Prothena Company Profile
(Get Rating)
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
- Get a free copy of the StockNews.com research report on Prothena (PRTA)
- Three Small-Cap Biotech Stocks to Consider Now
- Two Blue Chip Health Companies The Institutions Are Buying
- What To Expect From The Q4 Earnings Reporting Season
- Here’s What to Expect for the S&P 500 in 2023
- Can Bilibili be the Chinese Version of YouTube?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prothena, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Prothena wasn’t on the list.
While Prothena currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
